What is Quviviq?
Quviviq is a medication approved for the treatment of insomnia in adults [1]. It is available in 25mg tablet form [1].
How does Quviviq work?
Quviviq works by targeting the sleep-wake regulation system [1]. It is a dual orexin receptor antagonist (DORA) that inhibits the wake-promoting effect of orexin signaling in the brain, thereby promoting sleep [1].
When did Quviviq get approved?
Quviviq received FDA approval in January 2023 for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1].
What are the potential side effects of Quviviq?
Common side effects reported with Quviviq include sleepiness, headache, and dizziness [1]. Patients are advised to avoid activities requiring full mental alertness, such as driving or operating heavy machinery, for at least eight hours after taking the medication [1].
What is the recommended dosage for Quviviq?
The recommended dosage for Quviviq is 25mg taken orally once per night [1]. The medication should not be taken more than once a night or with any other sleep-aid medication [1].
Are there any safety concerns with Quviviq?
Quviviq carries a boxed warning regarding the risk of sleep paralysis, hallucinations, and suicidal thoughts and behaviors [1]. Patients experiencing these symptoms should contact their healthcare provider immediately [1]. The medication has also been associated with central nervous system depressant effects and potential for abuse or misuse [1].
How does Quviviq compare to other insomnia treatments?
Quviviq is a newer class of insomnia medication that acts on the orexin system, distinct from traditional hypnotics like benzodiazepines or Z-drugs [1]. Its dual orexin receptor antagonism aims to reduce hyperarousal associated with insomnia [1].
When does the patent for Quviviq expire?
Information regarding patent expiration for Quviviq is not publicly available within the provided context. DrugPatentWatch.com may offer more detailed patent information for medications [2].